Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04653597
Other study ID # APHP200013
Secondary ID 2020-A02036-33
Status Completed
Phase Phase 3
First received
Last updated
Start date May 16, 2021
Est. completion date April 12, 2023

Study information

Verified date July 2023
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A decreased level of consciousness is a common reason for presentation to the emergency department (ED) and is often the result of intoxication (up to 1% of all ED visits and 3% of ICU admission). In France, approximately 165 000 poisoned patients are managed each year. Originally developed in head injured patients, the Glasgow Coma Scale (GCS) is a validated reproducible score evaluating the level of consciousness: a GCS ≤ 8 is strongly associated with reduced gag reflex and increased incidence of aspiration pneumonia. Although recommended for patients with traumatic brain injury and coma, it remains unknown whether the benefit of an invasive management of airways with sedation, intubation and mechanical ventilation should be applied to other causes of coma in particular for acute poisoned patients. The investigator hypothesize that a conservative management with close monitoring without immediate endotracheal intubation of these patients is effective and associated with less in-hospital complications (truncated at 28 days) compared to routine practice management (in which the decision of immediate intubation is left to the discretion of the emergency physician).


Description:

A decreased level of consciousness is a common reason for presentation to the emergency department (ED) and is often the result of intoxication (up to 1% of all ED visits and 3% of intensive care unit (ICU) admission). In France, approximately 165 000 poisoned patients are managed each year.1 Originally developed in head injured patients, the Glasgow Coma Scale (GCS) is a validated reproducible score evaluating the level of consciousness - a GCS ≤ 8 is associated with reduced gag reflex and increased incidence of aspiration pneumonia (with an adjusted odds ratio of 2.32, 95%CI =1.60 to 3.33). However, whether this risk of aspiration pneumonia (AP) may be decreased by early intubation is unknown, and no difference in the risk of AP was reported between patients that were intubated early and patients who were not. Although it is well established that in trauma patients, a GCS ≤ 8 mandates airway management by endotracheal intubation, it remains unknown whether this strategy should be applied to other etiologies of coma, in particular for acute poisoned patients. Tracheal intubation and mechanical ventilation allow to prevent aspiration pneumonia, to optimize oxygenation and gas exchange. Investigators will include patients with a decreased level of consciousness (defined by a GCS of 8 or less) caused by acute intoxication (alcohol, recreative drugs, or other prescription drugs (with the exception intoxication with cardiotropic drugs, e.g. beta blockers, calcium channel inhibitor, angiotensin conversion enzyme)). These patients will be included at the initial stage of their management: in the ED, or out of hospital with a pre-hospital emergency physician. Patients with clear proven benefit of intubation will be excluded : patients in shock, patients with suspicion of brain lesion, seizure related with poisoning, visualization of regurgitation of gastric content or sign of respiratory distress. Conservative airway management. Patients will be conservatively managed, i.e. close monitoring and no intubation and mechanical ventilation unless the patient presents a clinical event that needs intubation (shock, sign of respiratory distress, visualization of regurgitation or seizure). Acute poisoning is a common reason for presentation to the ED or MICU intervention (up to 1% of all ED visits and 3% of intensive care unit (ICU) admission). These patients are often intubated (reported rate ranging from 20 to 50% in different cohort studies), when their GCS is below 8, in order to protect their airways. However there is currently no clear demonstration of its efficacy in this specific target population, while it is known that intubation is associated with morbidity and mortality. Intubated patients need subsequent intensive care unit admission and invasive monitoring, and this can be associated with increased risk of pulmonary complications, length of hospital-stay, nosocomial infections and cost. In a context of expenditures control in health care, appropriate intensive care resource utilization is an important issue. When considering the increasing demand for intensive care among emergency patients, the importance of health care resource allocation and expenditure control, and the possible absence benefit of intubation and intensive care, an endotracheal airway management of poisoned coma patients might be detrimental. Thus, if our hypothesis is demonstrated, the results of NICO study will change practice and guidelines for management of acute coma poisoned patients, with less exposure to the morbidity of endotracheal intubation and associated with decrease of ICU stay, and reduction of their health costs.


Recruitment information / eligibility

Status Completed
Enrollment 237
Est. completion date April 12, 2023
Est. primary completion date April 12, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years 2. Clinical suspicion of acute poisoning (either alcohol, drug or medication) 3. Decreased level of consciousness with a GCS = 8 assessed by an emergency physician either in the ED or in the out of hospital field with the mobile intensive care unit (MICU). 4. Written informed consent signed by the patient / the trustworthy person / family member / close relative or inclusion in case of emergency 5. Patients affiliated to French social security ("AME" excepted) Exclusion Criteria: 1. Respiratory failure (SpO2 < 90% with oxygen provided by nasal cannula (= 4 l/min.), clinical signs of respiratory distress) 2. Sustained systolic blood pressure < 90 mmHg despite fluid resuscitation of 1 liter of critalloid 3. Witnessed seizure 4. Acute cerebral aggression (Traumatic brain injury, intracranial hematoma, stroke) 5. Suspected Cardiotropic drugs poisoning (beta blockers, calcium channel inhibitor, angiotensin conversion enzyme), QRS or QT enlargement on ECG. 6. Suspected sole intoxication with toxic for which there is an antidote 7. Patient under legal protection measure (tutorship or curatorship) and patient deprived of freedom 8. Known Pregnant women and breast feeding woman 9. Participation in another intervention trial

Study Design


Intervention

Procedure:
Close monitoring
surveillance every 30 minutes of blood pressure, SpO2, respiratory rate, heart rate and GCS until the patient recovers a GCS>8 or responds adequately to a simple order
Endotracheal intubation
invasive airway management in order to avoid risk of pulmonary aspiration

Locations

Country Name City State
France Emergency department Hospital Pitié-Salpêtrière Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hierarchical composite endpoint of (truncated at 28 days): - In hospital death this endpoint will be reported using both the Finkelstein model (Finkelstein Stat med 1999; Beitler JAMA 2019) and the win ratio methods (Pocok Eur H J 2016), with priority listed in this order from highest to lowest. Patients will be followed until hospital discharge (or truncated at 28 days if still hospitalized) and data collected in the electronic health record the investigator with the help of a clinical research technician. at 28 days
Primary Hierarchical composite endpoint of (truncated at 28 days):- Length of ICU stay this endpoint will be reported using both the Finkelstein model (Finkelstein Stat med 1999; Beitler JAMA 2019) and the win ratio methods (Pocok Eur H J 2016), with priority listed in this order from highest to lowest. Patients will be followed until hospital discharge (or truncated at 28 days if still hospitalized) and data collected in the electronic health record the investigator with the help of a clinical research technician. at 28 days
Primary Hierarchical composite endpoint of (truncated at 28 days): - Length of hospital stay this endpoint will be reported using both the Finkelstein model (Finkelstein Stat med 1999; Beitler JAMA 2019) and the win ratio methods (Pocok Eur H J 2016), with priority listed in this order from highest to lowest. Patients will be followed until hospital discharge (or truncated at 28 days if still hospitalized) and data collected in the electronic health record the investigator with the help of a clinical research technician. at 28 days
Secondary In-hospital death (truncated at 28 days) number of included patients dead at 28 days after randomisation at 28 days
Secondary ICU length of stay (truncated at 28 days) number of day in ICU for each patient included since randomization at 28 days
Secondary Hospital length of stay (truncated at 28 days) number of day in hospitalization for each patient included since their randomization at 28 days
Secondary Proportion of patient with Mechanical ventilation at day 28 number of patient included with mechanical ventilation 28 days after randomization at 28 days
Secondary Lenght of mechanical ventilation until hospital discharge or at day28 at 28 days
Secondary Proportion of ICU admission number of patient included admitted to ICU during hospital stay 28 days
Secondary Proportion of rapid onset pneumonia number of patient included developing a rapid onset pneumonia during hospital stay 28 days
Secondary Adverse events from intubation (hypoxemia, dental trauma, regurgitation, cardiac arrest, intubation difficulty score (IDS) = 5, hypotension or esophageal intubation) number of patient included developing an adverse events from intubation during hospital stay, and type of adverse events 28 days
Secondary total hospital costs (truncated at 28 days) cost of hospitalization for patient included in the study. at 28 days
Secondary total hospital cost consequence analysis (truncated at 28 days) cost of hospitalization for patient included in the study. at 28 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Completed NCT02553070 - Health Professions Students and Faculty Perceptions of Poisoning Severity N/A
Recruiting NCT05215457 - Severity Index of Diquat Poisoning in Evaluating the Prognosis of Acute Diquat Poisoning
Completed NCT00015600 - Community-Based Environmental Health Intervention N/A
Recruiting NCT05098418 - Trends of Acute Intoxication in Poison Control Centre
Not yet recruiting NCT03314909 - Initial Hemopurification Strategy for Acute Paraquat Poisoning in Adults N/A
Not yet recruiting NCT03640143 - Effectiveness of Environmental Measures to Eliminate the Risks of Lead Exposure in Infant Lead Poisoning
Not yet recruiting NCT05229419 - Pattern of Acute Pediatric Poisoning at Assiut University Hospitals
Completed NCT00013754 - Pesticide Exposure Pathways for Farmworker Children N/A
Completed NCT04217070 - Suicidal Poisoning in Emergency Units
Withdrawn NCT03894306 - Understanding How Medication is Stored in the Home
Completed NCT00013767 - Community Based Prevention/Control Project N/A
Not yet recruiting NCT04729894 - Evaluating the Impact of a Safe Medication Storage Device N/A
Completed NCT01209455 - Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects N/A
Recruiting NCT04850014 - PBPK Modelling Applied to Acetaminophen Poisoned Obese Children